LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

First Leukemia Diagnostic Test Based on DNA Sequencing Detects up To 51 Gene Mutations

By LabMedica International staff writers
Posted on 02 Jan 2023
Print article
Image: The Lena Q51 leukemia diagnostic test will be launched in January 2023 (Photo courtesy of Alercell)
Image: The Lena Q51 leukemia diagnostic test will be launched in January 2023 (Photo courtesy of Alercell)

Until recently, a series of blood tests and a bone marrow biopsy were required when someone was "suspected" to have leukemia. It costs thousands of dollars and takes somewhere between six and nine weeks for a diagnosis. In addition to being time consuming, it is a subjective interpretation as cytology remains dependent on human interpretation. Until 2022 the only leukemia tests done could detect two gene mutations. Now, a new leukemia diagnostic test is capable of detecting 51 gene mutations, marking a significant technological and medical advancement.

Alercell, Inc. (Bozeman, MT, USA) is all set to launch LENA Q51(R) in January 2023. LENA Q51 is a leukemia diagnostic test based on sequencing DNA and can detect up to 51 gene alterations in leukemia patients. With LENA Q51, clinicians using a qPCR machine will be able to identify any gene mutations among 51 different genes in just three hours. By doing this, clinicians can determine the gene mutations in three hours via computer, eliminating the need for human interpretation. The information gathered will also enable clinicians to tailor the patient's treatment - all of this at a much lower cost. Alercell also plans to launch LENA S1, the first methylation-based molecular diagnostic test for lung cancer, in the first quarter of 2023. As an epigenetic regulator of gene expression, DNA methylation enables early diagnosis of lung cancer and very accurate localization of the disease, if present.

"I am thrilled that via the application of our knowledge of the genome, we are now able to produce very performing tests that will help people in finally avoiding the unpleasant traditional treatment," said Alercell co-founder Frederic Scheer.

Related Links:
Alercell, Inc.

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Sekisui Diagnostics UK Ltd.